UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

The lancet oncology, 2020-09, Vol.21 (9), p.1234-1243

2020

Volltextzugriff (PDF)

Neuroprotective Effects of 3,6′-Disinapoyl Sucrose Through Increased BDNF Levels and CREB Phosphorylation via the CaMKII and ERK1/2 Pathway

Journal of molecular neuroscience, 2014-08, Vol.53 (4), p.600-607

2014

Volltextzugriff (PDF)

A potential peptide therapeutic derived from the juxtamembrane domain of the epidermal growth factor receptor

PloS one, 2012-11, Vol.7 (11), p.e49702-e49702

2012

Volltextzugriff (PDF)

The regulatory role of the juxtamembrane region in the activity of the epidermal growth factor receptor

Biochemical Society transactions, 2012-02, Vol.40 (1), p.195-199

Boran, Aislyn D W

2012

Volltextzugriff (PDF)

Recovering protein-protein and domain-domain interactions from aggregation of IP-MS proteomics of coregulator complexes

PLoS computational biology, 2011-12, Vol.7 (12), p.e1002319-e1002319

2011

Volltextzugriff (PDF)

Genomic signatures defining responsiveness to allopurinol and combination therapy for lung cancer identified by systems therapeutics analyses

Molecular oncology, 2019-08, Vol.13 (8), p.1725-1743

2019

Volltextzugriff (PDF)

Abstract CT025: Dabrafenib plus trametinib in BRAF V600E-mutant high-grade (HGG) and low-grade glioma (LGG)

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT025-CT025

2021

Volltextzugriff (PDF)

Identification of new G beta gamma interaction sites in adenylyl cyclase 2

Cellular signalling, 2011-09, Vol.23 (9), p.1489-1495

2011

Volltextzugriff (PDF)

Identification of new Gβγ interaction sites in adenylyl cyclase 2

Cellular signalling, 2011-09, Vol.23 (9), p.1489-1495

2011

Volltextzugriff (PDF)

Systems approaches to polypharmacology and drug discovery

Current opinion in drug discovery & development, 2010-05, Vol.13 (3), p.297

2010

Volltextzugriff (PDF)

Systems Pharmacology

The Mount Sinai journal of medicine, 2010-07, Vol.77 (4), p.333-344

2010

Volltextzugriff (PDF)

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Nature medicine, 2023-05, Vol.29 (5), p.1103-1112

2023

Volltextzugriff (PDF)

A phase II trial of JDQ443 in KRAS G12C -mutated NSCLC with PD-L1 expression <1% or PD-L1 expression ≥1% and an STK11 co-mutation

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS9158-TPS9158

2023

Volltextzugriff (PDF)

RARE-11. EFFICACY AND SAFETY OF DABRAFENIB + TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED LOW-GRADE GLIOMA (LGG)

Neuro-oncology (Charlottesville, Va.), 2018-11, Vol.20 (suppl_6), p.vi238-vi239

2018

Volltextzugriff (PDF)

ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)

Neuro-oncology (Charlottesville, Va.), 2019-11, Vol.21 (Suppl 6), p.vi19-vi20

2019

Volltextzugriff (PDF)

KontRASt-02: A phase III trial investigating the efficacy and safety of the KRAS G12C inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C -mutated NSCLC

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS9144-TPS9144

2023

Volltextzugriff (PDF)

Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial

The lancet oncology, 2024-10, Vol.25 (10), p.1357-1370

2024

Volltextzugriff (PDF)

Abstract PO2-19-06: An Open-label, Interventional, Multicenter Study of Trastuzumab Deruxtecan Monotherapy in Patients With Unresectable and/or Metastatic HER2-Low or HER2 Immunohistochemistry 0 Breast Cancer: DESTINY-Breast15

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.PO2-19-06-PO2-19-06

2024

Volltextzugriff (PDF)

Abstract CT120: A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM)

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT120-CT120

2019

Volltextzugriff (PDF)

Dabrafenib plus trametinib in patients with BRAF V600E -mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

The lancet oncology, 2020-09, Vol.21 (9), p.1234

2020

Volltextzugriff (PDF)

Abstract CT048: A Phase II trial of JDQ443 in KRAS G12C- mutated NSCLC with PD-L1 expression <1% or PD-L1 expression≥1% and an STK11 co-mutation

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT048-CT048

2023

Volltextzugriff (PDF)

Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated biliary tract cancer (BTC): A cohort of the ROAR basket trial

Journal of clinical oncology, 2019-02, Vol.37 (4_suppl), p.187-187

2019

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(31)

Sprache

Englisch
(31)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

Neuroprotective Effects of 3,6′-Disinapoyl Sucrose Through Increased BDNF Levels and CREB Phosphorylation via the CaMKII and ERK1/2 Pathway

A potential peptide therapeutic derived from the juxtamembrane domain of the epidermal growth factor receptor

The regulatory role of the juxtamembrane region in the activity of the epidermal growth factor receptor

Recovering protein-protein and domain-domain interactions from aggregation of IP-MS proteomics of coregulator complexes

Genomic signatures defining responsiveness to allopurinol and combination therapy for lung cancer identified by systems therapeutics analyses

Abstract CT025: Dabrafenib plus trametinib in BRAF V600E-mutant high-grade (HGG) and low-grade glioma (LGG)

Identification of new G beta gamma interaction sites in adenylyl cyclase 2

Identification of new Gβγ interaction sites in adenylyl cyclase 2

Systems approaches to polypharmacology and drug discovery

Systems Pharmacology

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

A phase II trial of JDQ443 in KRAS G12C -mutated NSCLC with PD-L1 expression <1% or PD-L1 expression ≥1% and an STK11 co-mutation

RARE-11. EFFICACY AND SAFETY OF DABRAFENIB + TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED LOW-GRADE GLIOMA (LGG)

ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)

Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial

KontRASt-02: A phase III trial investigating the efficacy and safety of the KRAS G12C inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C -mutated NSCLC

Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial

Abstract PO2-19-06: An Open-label, Interventional, Multicenter Study of Trastuzumab Deruxtecan Monotherapy in Patients With Unresectable and/or Metastatic HER2-Low or HER2 Immunohistochemistry 0 Breast Cancer: DESTINY-Breast15

Abstract CT120: A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM)

Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

Dabrafenib plus trametinib in patients with BRAF V600E -mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

Dabrafenib plus trametinib in patients with BRAF V600E -mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

Abstract CT048: A Phase II trial of JDQ443 in KRAS G12C- mutated NSCLC with PD-L1 expression <1% or PD-L1 expression≥1% and an STK11 co-mutation

Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated biliary tract cancer (BTC): A cohort of the ROAR basket trial

Suchergebnisse filtern